Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

Original from: business wire

Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

“We are pleased that Exact Sciences is acquiring Resolution Bioscience,” said Sam Raha, senior vice president, Agilent, and president, Diagnostics and Genomics Group. “Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction.”

“We are excited to work with the Resolution Bioscience team to integrate their innovative diagnostics into our Precision Oncology portfolio,” said Brian Baranick, general manager of Precision Oncology at Exact Sciences. “Resolution Bioscience’s high-quality liquid therapy selection platform perfectly complements our OncoExTra test, allowing Exact Sciences to help more cancer patients determine their best treatment options.”

Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions. Agilent acquired the company in 2021.

Sources: Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience